Cancer immunotherapy candidate provokes powerful dual response in cancer and immune cells
Cancer immunotherapy drugs called PD-1 inhibitors are widely used to stimulate the immune system to fight cancer, but many patients either don’t respond or develop resistance to them. A new small-molecule drug candidate being tested in an early-stage clinical trial aims to improve patient responses to immunotherapy.
Now scientists have shown, in a study published today in Nature, that the small molecule works through two different mechanisms to slow tumor growth and increase survival in lab animals.
Researchers from the Tumor ...











